Literature DB >> 1702726

Induction of tolerance in peripheral T cells with monoclonal antibodies.

S X Qin1, M Wise, S P Cobbold, L Leong, Y C Kong, J R Parnes, H Waldmann.   

Abstract

Our goal has been to develop ways to tolerize the mature immune system to any defined antigen. In this report we show that peripheral (post-thymic) T cells of mice can become tolerant to a range of antigens (human and rat immunoglobulins, and bone marrow and skin grafts that differ at multiple minor transplantation antigens). In the case of human gamma globulin (HGG), this required that the antigen be given under the cover of a short course of non-depleting anti-CD4 antibody, while for tolerance to skin and marrow grafts anti-CD8 antibody was also required. Tolerance to HGG could be reinforced by repeated injections of HGG, but was lost in the absence of any further exposure to antigen. This reversal of tolerance with time was due to new T cells being exported from the thymus, as it was not observed in tolerized, adult thymectomized mice. In contrast, tolerance to marrow and skin grafts was permanent, presumably because the established grafts acted as a continuous source of antigen to reinforce the tolerant state. Tolerance could not be broken by the infusion of unprimed spleen cells and in one example (tolerance to Mls-1a) there was clear evidence that specific peripheral T cells were anergic. We propose that anergic cells may themselves participate in reinforcing the tolerant state by competing at sites of antigen presentation.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1702726     DOI: 10.1002/eji.1830201231

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  48 in total

1.  T cell-independent rescue of B lymphocytes from peripheral immune tolerance.

Authors:  V Kouskoff; G Lacaud; D Nemazee
Journal:  Science       Date:  2000-03-31       Impact factor: 47.728

Review 2.  Mechanisms of self-nonself discrimination and possible clinical relevance.

Authors:  Carolin Daniel; Jens Nolting; Harald von Boehmer
Journal:  Immunotherapy       Date:  2009-07       Impact factor: 4.196

3.  Comparative analysis of lesion development and intraspinal inflammation in four strains of mice following spinal contusion injury.

Authors:  Kristina A Kigerl; Violeta M McGaughy; Phillip G Popovich
Journal:  J Comp Neurol       Date:  2006-02-01       Impact factor: 3.215

4.  Natural Tregs, CD4+CD25+ inhibitory hybridomas, and their cell contact dependent suppression.

Authors:  Elizabeth H Field; Katarina Kulhankova; Mohamed E Nasr
Journal:  Immunol Res       Date:  2007       Impact factor: 2.829

5.  Reshaping a therapeutic CD4 antibody.

Authors:  S D Gorman; M R Clark; E G Routledge; S P Cobbold; H Waldmann
Journal:  Proc Natl Acad Sci U S A       Date:  1991-05-15       Impact factor: 11.205

6.  CD8 blockade promotes the expansion of antigen-specific CD4+ FOXP3+ regulatory T cells in vivo.

Authors:  Z Wang; J D Davies
Journal:  Int Immunopharmacol       Date:  2006-11-28       Impact factor: 4.932

7.  Regulation and privilege in transplantation tolerance.

Authors:  Herman Waldmann; Elizabeth Adams; Paul Fairchild; Stephen Cobbold
Journal:  J Clin Immunol       Date:  2008-09-06       Impact factor: 8.317

8.  Pharmacokinetics/pharmacodynamics of nondepleting anti-CD4 monoclonal antibody (TRX1) in healthy human volunteers.

Authors:  Chee M Ng; Eric Stefanich; Banmeet S Anand; Paul J Fielder; Louis Vaickus
Journal:  Pharm Res       Date:  2006-11-30       Impact factor: 4.200

9.  Production of erythrocyte autoantibodies in NZB mice is inhibited by CD4 antibodies.

Authors:  G G Oliveira; P R Hutchings; I M Roitt; P M Lydyard
Journal:  Clin Exp Immunol       Date:  1994-05       Impact factor: 4.330

10.  A comparative study of T-cell receptor V beta usage in non-obese diabetic (NOD) and I-E transgenic NOD mice.

Authors:  N M Parish; H Acha-Orbea; E Simpson; S X Qin; T Lund; A Cooke
Journal:  Immunology       Date:  1993-04       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.